Literature DB >> 20520633

Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis.

P Guglielmelli, F Biamonte, A Spolverini, L Pieri, A Isgrò, E Antonioli, A Pancrazzi, A Bosi, G Barosi, A M Vannucchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20520633     DOI： 10.1038/leu.2010.126

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  7 in total

1.  Inherited predisposition to myeloproliferative neoplasms.

Authors:  Amy V Jones; Nicholas C P Cross
Journal:  Ther Adv Hematol       Date:  2013-08

2.  The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients.

Authors:  Xinju Zhang; Tingting Hu; Zhiyuan Wu; Zhihua Kang; Weiwei Liu; Ming Guan
Journal:  Int J Hematol       Date:  2012-09-29       Impact factor: 2.490

3.  The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.

Authors:  Grzegorz Helbig; Agata Wieczorkiewicz; Krzysztof Woźniczka; Katarzyna Wiśniewska-Piąty; Anna Rusek; Sławomira Kyrcz-Krzemień
Journal:  Med Oncol       Date:  2012-03-01       Impact factor: 3.064

4.  TERT and JAK2 polymorphisms define genetic predisposition to myeloproliferative neoplasms in Japanese patients.

Authors:  Masafumi Matsuguma; Toshiaki Yujiri; Kaoru Yamamoto; Yasuko Kajimura; Yoshihiro Tokunaga; Mayumi Tanaka; Yoshinori Tanaka; Yukinori Nakamura; Yukio Tanizawa
Journal:  Int J Hematol       Date:  2019-09-30       Impact factor: 2.490

5.  Convergent mechanisms of somatic mutations in polycythemia vera.

Authors:  Kai Wang; Sabina Swierczek; Kimberly Hickman; Hakon Hakonarson; Josef T Prchal
Journal:  Discov Med       Date:  2011-07       Impact factor: 2.970

6.  Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.

Authors:  A Tefferi; O Abdel-Wahab; F Cervantes; J D Crispino; G Finazzi; F Girodon; H Gisslinger; J Gotlib; J-J Kiladjian; R L Levine; J D Licht; A Mullally; O Odenike; A Pardanani; R T Silver; E Solary; T Mughal
Journal:  Blood Cancer J       Date:  2011-03-04       Impact factor: 11.037

Review 7.  The JAK2 GGCC (46/1) Haplotype in Myeloproliferative Neoplasms: Causal or Random?

Authors:  Luisa Anelli; Antonella Zagaria; Giorgina Specchia; Francesco Albano
Journal:  Int J Mol Sci       Date:  2018-04-11       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.